Attorneys from McDermott Will & Schulte review the costs, benefits and risks for employers to evaluate when deciding how their benefits address these popular medications.
Changes in plan design, coupled with regulatory improvements and market evolution, mean concerns about collective investment trusts should no longer keep them from 403(b) plans.